Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN)

Tipranks - Tipranks - Thu Apr 16, 6:31AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN) with bullish sentiments.

Claim 30% Off TipRanks

AbbVie (ABBV)

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie, with a price target of $270.00. The company’s shares closed last Tuesday at $210.26, close to its 52-week high of $218.66.

According to TipRanks.com, Flynn is a 5-star analyst with an average return of 9.0% and a 54.4% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Arvinas Holding Company, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on AbbVie is a Moderate Buy with an average price target of $254.28, which is a 24.2% upside from current levels. In a report issued on April 4, TipRanks – PerPlexity also upgraded the stock to Buy with a $233.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

McKesson (MCK)

Bank of America Securities analyst Allen Lutz maintained a Buy rating on McKesson today and set a price target of $1000.00. The company’s shares closed last Tuesday at $862.79.

According to TipRanks.com, Lutz is a 5-star analyst with an average return of 10.7% and a 61.9% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Hims & Hers Health, and Envista Holdings. ;'>

McKesson has an analyst consensus of Strong Buy, with a price target consensus of $981.22, a 13.7% upside from current levels. In a report issued on April 8, Evercore ISI also maintained a Buy rating on the stock with a $950.00 price target.

Regeneron (REGN)

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Regeneron, with a price target of $860.00. The company’s shares closed last Tuesday at $755.51.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 2.5% and a 51.8% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Bicara Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $876.36 average price target, implying a 17.6% upside from current levels. In a report issued on March 31, Piper Sandler also initiated coverage with a Buy rating on the stock with a $875.00 price target.

Read More on ABBV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).